BridgeBio Pharma, a commercial-stage company, reported narrower net loss for its fourth quarter due to revenue growth from improved product sales. The company’s total quarterly revenue increased to $154.18 million, driven by a significant increase in net product revenue from Attruby.
For the full year 2025, BridgeBio’s net loss widened to $724.93 million, despite revenue growth. However, the company reported three positive Phase 3 trial readouts for its candidates in three months and highlighted key milestones ahead for its drug pipeline.
The lead transthyretin stabiliser Attruby is approved in several countries, including the US, EU, Japan, Switzerland, and the UK. New data on Attruby will be presented at the American College of Cardiology Annual Scientific Sessions & Expo in March 2026.
BridgeBio’s pipeline includes BBP-418 for Limb-girdle muscular dystrophy type 2I/R9, Encaleret for Autosomal Dominant Hypocalcemia Type 1, and Infigratinib for achondroplasia. The company expects to submit a New Drug Application to the FDA in the first half of 2026.
As of December 31, 2025, BridgeBio had $587.5 million in cash, cash equivalents, and marketable securities, down from $681.1 million in the prior year. The stock closed Tuesday’s trade at $68.31, up 0.59%.
Source: https://www.nasdaq.com/articles/bridgebio-pharma-reports-narrower-net-loss-q4-revenue-zooms-attruby-sales